Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of lithium carbonate in amyotrophic lateral sclerosis (LISLA)
2008-003707-32Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lithium carbonate in amyotrophic lateral sclerosis (ALS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Survival at 15 months. Started Aug 2008; status: active.
02
Drugs
lithium carbonate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2008-003707-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003707-32.